English

Autolus Therapeutics plc

EDGAR

AUTL Registration statement (S-3) · filed 2026-09-14

Annual consolidated revenue for 2025: about USD 75.39M, using the latest reported figures. The previous period, 2024, was about USD 10.12M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

45.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 45689000 USD Source

Operating margin

-95.95%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -43838000 USD Source
Revenue: 45689000 USD Source

Operating cash flow

-25.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -90386000 USD Source
Operating Cash Flow: -65317000 USD Source

Free cash flow

-26 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -90386000 USD Source
Operating Cash Flow: -65317000 USD Source
Capital Expenditure: 3601000 USD Source
Capital Expenditure: 2688000 USD Source

Cash and cash equivalents: 171 million USD 2026-06-30 Source
Exact value

171400000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

117 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 21194000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 75388000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 51099000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 26218000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 45689000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-280 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -79118000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -287528000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -197196000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -71598000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -39111000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-226 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -216245000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -148346000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -283568000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -216245000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -65317000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -90386000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -65317000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+644.9%

Prior period

USD 10.12 million

2024-01-01 – 2024-12-31
Current period

USD 75.39 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

75388000 − 10120000 = 65268000 USD

10120000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
75388000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Year-over-year change in Revenue: 65268000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 75388000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2037269 Filing: 000173046326000038 Input fundies:Revenue: 10120000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2038044 Filing: 000173046326000038
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 66.87 million

Prior period

−USD 220.66 million

2024-01-01 – 2024-12-31
Current period

−USD 287.53 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-287528000 − -220662000 = -66866000 USD

-220662000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-287528000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Year-over-year change in Net income: -66866000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -287528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2969247 Filing: 000173046326000038 Input fundies:NetIncome: -220662000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2970021 Filing: 000173046326000038
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 77.3 million

Prior period

−USD 206.27 million

2024-01-01 – 2024-12-31
Current period

−USD 283.57 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-283568000 − -206271000 = -77297000 USD

-206271000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-283568000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Year-over-year change in Operating cash flow: -77297000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -283568000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2263616 Filing: 000173046326000038 Input fundies:OperatingCashFlow: -206271000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2264270 Filing: 000173046326000038
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-13.7%

Prior period

USD 22.08 million

2024-01-01 – 2024-12-31
Current period

USD 19.04 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

19043000 − 22075000 = -3032000 USD

22075000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
19043000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Year-over-year change in Capital expenditure: -3032000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 19043000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266025 Filing: 000173046326000038 Input fundies:CapitalExpenditure: 22075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266617 Filing: 000173046326000038
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 75.39 million 100% of revenue
Cost of revenue USD 96.37 million 128% of revenue
Operating expenses USD 249.56 million 331% of revenue
Operating income −USD 270.54 million −359% of revenue
Tax, interest and other Derived USD 16.98 million 23% of revenue
Net income −USD 287.53 million −381% of revenue

Cash

Operating cash flow −USD 283.57 million −376% of revenue
Capital expenditure USD 19.04 million 25% of revenue
Free cash flow Derived −USD 302.61 million −401% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Operating loss: operating costs were 1,483% of revenue.
2018 Operating loss: operating costs were 4,189% of revenue.
2019 Operating loss: operating costs were 5,123% of revenue.
2023 Operating loss: operating costs were 10,683% of revenue.
2024 Operating loss: operating costs were 2,486% of revenue.
2025 Operating loss: operating costs were 459% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2015-10-01 – 2016-09-30	1212000	Unavailable	Unavailable	Unavailable	-12550000	-11704000 Derived	Source 2015-10-01 – 2016-09-30: 1212000 USD Inspect Revenue Open source 2015-10-01 – 2016-09-30: -12550000 USD Inspect Net Income Open source 2015-10-01 – 2016-09-30: -9849000 USD Inspect Operating Cash Flow Open source 2015-10-01 – 2016-09-30: 1855000 USD Inspect Capital Expenditure Open source
2017 2016-10-01 – 2017-09-30	1693000	25111000 Derived	-23418000	-3718000 Derived	-19700000	-19236000 Derived	Source 2016-10-01 – 2017-09-30: 1693000 USD Inspect Revenue Open source 2016-10-01 – 2017-09-30: -23418000 USD Inspect Operating Income Open source 2016-10-01 – 2017-09-30: -19700000 USD Inspect Net Income Open source 2016-10-01 – 2017-09-30: -16360000 USD Inspect Operating Cash Flow Open source 2016-10-01 – 2017-09-30: 2876000 USD Inspect Capital Expenditure Open source
2018 2017-10-01 – 2018-09-30	1407000	58940000 Derived	-57533000	-12782000 Derived	-44751000	-40656000 Derived	Source 2017-10-01 – 2018-09-30: 1407000 USD Inspect Revenue Open source 2017-10-01 – 2018-09-30: -57533000 USD Inspect Operating Income Open source 2017-10-01 – 2018-09-30: -44751000 USD Inspect Net Income Open source 2017-10-01 – 2018-09-30: -31537000 USD Inspect Operating Cash Flow Open source 2017-10-01 – 2018-09-30: 9119000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	2908000	148972000 Derived	-146064000	-22264000 Derived	-123800000	-119825000 Derived	Source 2019-01-01 – 2019-12-31: 2908000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -146064000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -123800000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -101484000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 18341000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1698000	181399000 Derived	-179701000	28682000 Derived	-208383000	-156573000 Derived	Source 2023-01-01 – 2023-12-31: 1698000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -179701000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -208383000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -145587000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 10986000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	10120000	251546000 Derived	-241426000	-20764000 Derived	-220662000	-228346000 Derived	Source 2024-01-01 – 2024-12-31: 10120000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -241426000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -220662000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -206271000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 22075000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	75388000	345932000 Derived	-270544000	16984000 Derived	-287528000	-302611000 Derived	Source 2025-01-01 – 2025-12-31: 75388000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -270544000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -287528000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -283568000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 19043000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 75.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-09-30	Revenue	1212000	Revenue: 1212000 Open source
20172017-09-30	Revenue	1693000	Revenue: 1693000 Open source
20182018-09-30	Revenue	1407000	Revenue: 1407000 Open source
20192019-12-31	Revenue	2908000	Revenue: 2908000 Open source
20232023-12-31	Revenue	1698000	Revenue: 1698000 Open source
20242024-12-31	Revenue	10120000	Revenue: 10120000 Open source
20252025-12-31	Revenue	75388000	Revenue: 75388000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

644.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-09-30	Year over year	No prior comparable period	Revenue: 1212000 Open source
20172017-09-30	Year over year	39.7%	Revenue: 1693000 Open source Revenue: 1212000 Open source
20182018-09-30	Year over year	-16.9%	Revenue: 1407000 Open source Revenue: 1693000 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 2908000 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 1698000 Open source
20242024-12-31	Year over year	496%	Revenue: 10120000 Open source Revenue: 1698000 Open source
20252025-12-31	Year over year	644.9%	Revenue: 75388000 Open source Revenue: 10120000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -358.9% 2025

Net margin -381.4% 2025

Free cash flow margin -401.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2016-09-30	Operating margin	Not reported	Revenue: 1212000 Open source
20172017-09-30	Operating margin	-1,383.2%	Operating Income: -23418000 Open source Revenue: 1693000 Open source
20182018-09-30	Operating margin	-4,089.1%	Operating Income: -57533000 Open source Revenue: 1407000 Open source
20192019-12-31	Operating margin	-5,022.8%	Operating Income: -146064000 Open source Revenue: 2908000 Open source
20232023-12-31	Operating margin	-10,583.1%	Operating Income: -179701000 Open source Revenue: 1698000 Open source
20242024-12-31	Operating margin	-2,385.6%	Operating Income: -241426000 Open source Revenue: 10120000 Open source
20252025-12-31	Operating margin	-358.9%	Operating Income: -270544000 Open source Revenue: 75388000 Open source
20162016-09-30	Net margin	-1,035.5%	Net Income: -12550000 Open source Revenue: 1212000 Open source
20172017-09-30	Net margin	-1,163.6%	Net Income: -19700000 Open source Revenue: 1693000 Open source
20182018-09-30	Net margin	-3,180.6%	Net Income: -44751000 Open source Revenue: 1407000 Open source
20192019-12-31	Net margin	-4,257.2%	Net Income: -123800000 Open source Revenue: 2908000 Open source
20232023-12-31	Net margin	-12,272.3%	Net Income: -208383000 Open source Revenue: 1698000 Open source
20242024-12-31	Net margin	-2,180.5%	Net Income: -220662000 Open source Revenue: 10120000 Open source
20252025-12-31	Net margin	-381.4%	Net Income: -287528000 Open source Revenue: 75388000 Open source
20162016-09-30	Free cash flow margin	-965.7%	Revenue: 1212000 Open source Operating Cash Flow: -9849000 Open source Capital Expenditure: 1855000 Open source
20172017-09-30	Free cash flow margin	-1,136.2%	Revenue: 1693000 Open source Operating Cash Flow: -16360000 Open source Capital Expenditure: 2876000 Open source
20182018-09-30	Free cash flow margin	-2,889.6%	Revenue: 1407000 Open source Operating Cash Flow: -31537000 Open source Capital Expenditure: 9119000 Open source
20192019-12-31	Free cash flow margin	-4,120.5%	Revenue: 2908000 Open source Operating Cash Flow: -101484000 Open source Capital Expenditure: 18341000 Open source
20232023-12-31	Free cash flow margin	-9,221%	Revenue: 1698000 Open source Operating Cash Flow: -145587000 Open source Capital Expenditure: 10986000 Open source
20242024-12-31	Free cash flow margin	-2,256.4%	Revenue: 10120000 Open source Operating Cash Flow: -206271000 Open source Capital Expenditure: 22075000 Open source
20252025-12-31	Free cash flow margin	-401.4%	Revenue: 75388000 Open source Operating Cash Flow: -283568000 Open source Capital Expenditure: 19043000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -283.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-09-30	Operating cash flow	-9849000	Operating Cash Flow: -9849000 Open source
20172017-09-30	Operating cash flow	-16360000	Operating Cash Flow: -16360000 Open source
20182018-09-30	Operating cash flow	-31537000	Operating Cash Flow: -31537000 Open source
20192019-12-31	Operating cash flow	-101484000	Operating Cash Flow: -101484000 Open source
20232023-12-31	Operating cash flow	-145587000	Operating Cash Flow: -145587000 Open source
20242024-12-31	Operating cash flow	-206271000	Operating Cash Flow: -206271000 Open source
20252025-12-31	Operating cash flow	-283568000	Operating Cash Flow: -283568000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -302.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-09-30	Free cash flow	-11704000	Operating Cash Flow: -9849000 Open source Capital Expenditure: 1855000 Open source
20172017-09-30	Free cash flow	-19236000	Operating Cash Flow: -16360000 Open source Capital Expenditure: 2876000 Open source
20182018-09-30	Free cash flow	-40656000	Operating Cash Flow: -31537000 Open source Capital Expenditure: 9119000 Open source
20192019-12-31	Free cash flow	-119825000	Operating Cash Flow: -101484000 Open source Capital Expenditure: 18341000 Open source
20232023-12-31	Free cash flow	-156573000	Operating Cash Flow: -145587000 Open source Capital Expenditure: 10986000 Open source
20242024-12-31	Free cash flow	-228346000	Operating Cash Flow: -206271000 Open source Capital Expenditure: 22075000 Open source
20252025-12-31	Free cash flow	-302611000	Operating Cash Flow: -283568000 Open source Capital Expenditure: 19043000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

69.8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-09-30	Liabilities / assets	Not reported	No source recorded
20172017-09-30	Liabilities / assets	4.1%	Total Liabilities: 6061000 Open source Total Assets: 148662000 Open source
20182018-09-30	Liabilities / assets	6.5%	Total Liabilities: 17740000 Open source Total Assets: 273205000 Open source
20192019-12-31	Liabilities / assets	16%	Total Liabilities: 48694000 Open source Total Assets: 303533000 Open source
20232023-12-31	Liabilities / assets	70.3%	Total Liabilities: 263907000 Open source Total Assets: 375381000 Open source
20242024-12-31	Liabilities / assets	45.4%	Total Liabilities: 355400000 Open source Total Assets: 782725000 Open source
20252025-12-31	Liabilities / assets	69.8%	Total Liabilities: 410939000 Open source Total Assets: 589068000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.94× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-09-30	Current assets / current liabilities	Not reported	No source recorded
20172017-09-30	Current assets / current liabilities	28.31×	Current Assets: 142482000 Open source Current Liabilities: 5033000 Open source
20182018-09-30	Current assets / current liabilities	15.13×	Current Assets: 259278000 Open source Current Liabilities: 17139000 Open source
20192019-12-31	Current assets / current liabilities	9.98×	Current Assets: 249256000 Open source Current Liabilities: 24984000 Open source
20232023-12-31	Current assets / current liabilities	6.15×	Current Assets: 275302000 Open source Current Liabilities: 44737000 Open source
20242024-12-31	Current assets / current liabilities	10.88×	Current Assets: 660929000 Open source Current Liabilities: 60743000 Open source
20252025-12-31	Current assets / current liabilities	5.94×	Current Assets: 435915000 Open source Current Liabilities: 73440000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2015-10-01 – 2016-09-30	−USD 12.55 million Exact value Exact value: -12550000 USD 2015-10-01 – 2016-09-30: -12550000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2016-09-30 Autolus Therapeutics plc (edgar:1730463) Net Income: -12550000 USD Concept: fundies:NetIncome Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:NetIncome: -12550000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autl-20181231.xml#210981 Filing: 000173046319000004 The citation records this snapshot. The page link may show a newer release later.	−USD 9.85 million Exact value Exact value: -9849000 USD 2015-10-01 – 2016-09-30: -9849000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2016-09-30 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -9849000 USD Concept: fundies:OperatingCashFlow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9849000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autl-20181231.xml#209769 Filing: 000173046319000004 The citation records this snapshot. The page link may show a newer release later.	USD 1.86 million Exact value Exact value: 1855000 USD 2015-10-01 – 2016-09-30: 1855000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2016-09-30 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 1855000 USD Concept: fundies:CapitalExpenditure Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1855000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autl-20181231.xml#224226 Filing: 000173046319000004 The citation records this snapshot. The page link may show a newer release later.	−USD 11.7 million Calculation and evidence -9849000 − 1855000 USD Exact free cash flow: -11704000 USD 2015-10-01 – 2016-09-30: -9849000 USD · Inspect Operating Cash Flow · Source 2015-10-01 – 2016-09-30: 1855000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2016-09-30 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -11704000 USD Concept: free-cash-flow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9849000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autl-20181231.xml#209769 Filing: 000173046319000004 Input fundies:CapitalExpenditure: 1855000 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autl-20181231.xml#224226 Filing: 000173046319000004 The citation records this snapshot. The page link may show a newer release later.
2017 2016-10-01 – 2017-09-30	−USD 19.7 million Exact value Exact value: -19700000 USD 2016-10-01 – 2017-09-30: -19700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2017-09-30 Autolus Therapeutics plc (edgar:1730463) Net Income: -19700000 USD Concept: fundies:NetIncome Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:NetIncome: -19700000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#212146 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.	−USD 16.36 million Exact value Exact value: -16360000 USD 2016-10-01 – 2017-09-30: -16360000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2017-09-30 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -16360000 USD Concept: fundies:OperatingCashFlow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16360000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#210800 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.	USD 2.88 million Exact value Exact value: 2876000 USD 2016-10-01 – 2017-09-30: 2876000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2017-09-30 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 2876000 USD Concept: fundies:CapitalExpenditure Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2876000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#227413 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.	−USD 19.24 million Calculation and evidence -16360000 − 2876000 USD Exact free cash flow: -19236000 USD 2016-10-01 – 2017-09-30: -16360000 USD · Inspect Operating Cash Flow · Source 2016-10-01 – 2017-09-30: 2876000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2017-09-30 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -19236000 USD Concept: free-cash-flow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16360000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#210800 Filing: 000162828020002797 Input fundies:CapitalExpenditure: 2876000 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#227413 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.
2018 2017-10-01 – 2018-09-30	−USD 44.75 million Exact value Exact value: -44751000 USD 2017-10-01 – 2018-09-30: -44751000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2018-09-30 Autolus Therapeutics plc (edgar:1730463) Net Income: -44751000 USD Concept: fundies:NetIncome Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:NetIncome: -44751000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046321000004/autl-20201231.htm#2016634 Filing: 000173046321000004 The citation records this snapshot. The page link may show a newer release later.	−USD 31.54 million Exact value Exact value: -31537000 USD 2017-10-01 – 2018-09-30: -31537000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2018-09-30 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -31537000 USD Concept: fundies:OperatingCashFlow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31537000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#210580 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.	USD 9.12 million Exact value Exact value: 9119000 USD 2017-10-01 – 2018-09-30: 9119000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2018-09-30 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 9119000 USD Concept: fundies:CapitalExpenditure Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2018-09-30&surface=latest&period_type=duration&start=2017-10-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9119000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#227195 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.	−USD 40.66 million Calculation and evidence -31537000 − 9119000 USD Exact free cash flow: -40656000 USD 2017-10-01 – 2018-09-30: -31537000 USD · Inspect Operating Cash Flow · Source 2017-10-01 – 2018-09-30: 9119000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2018-09-30 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -40656000 USD Concept: free-cash-flow Period: 2017-10-01 to 2018-09-30 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31537000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#210580 Filing: 000162828020002797 Input fundies:CapitalExpenditure: 9119000 USD (2017-10-01 to 2018-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/autl-20191231.xml#227195 Filing: 000162828020002797 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 123.8 million Exact value Exact value: -123800000 USD 2019-01-01 – 2019-12-31: -123800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2019-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -123800000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123800000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046322000007/autl-20211231.htm#2402141 Filing: 000173046322000007 The citation records this snapshot. The page link may show a newer release later.	−USD 101.48 million Exact value Exact value: -101484000 USD 2019-01-01 – 2019-12-31: -101484000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2019-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -101484000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -101484000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046322000007/autl-20211231.htm#2301469 Filing: 000173046322000007 The citation records this snapshot. The page link may show a newer release later.	USD 18.34 million Exact value Exact value: 18341000 USD 2019-01-01 – 2019-12-31: 18341000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2019-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 18341000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18341000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046322000007/autl-20211231.htm#2305454 Filing: 000173046322000007 The citation records this snapshot. The page link may show a newer release later.	−USD 119.83 million Calculation and evidence -101484000 − 18341000 USD Exact free cash flow: -119825000 USD 2019-01-01 – 2019-12-31: -101484000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 18341000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2019-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -119825000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -101484000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046322000007/autl-20211231.htm#2301469 Filing: 000173046322000007 Input fundies:CapitalExpenditure: 18341000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046322000007/autl-20211231.htm#2305454 Filing: 000173046322000007 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 142.09 million Exact value Exact value: -142094000 USD 2020-01-01 – 2020-12-31: -142094000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2020-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -142094000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -142094000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000016/autl-20221231.htm#3075876 Filing: 000173046323000016 The citation records this snapshot. The page link may show a newer release later.	−USD 117.76 million Exact value Exact value: -117758000 USD 2020-01-01 – 2020-12-31: -117758000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2020-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -117758000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117758000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000016/autl-20221231.htm#2373184 Filing: 000173046323000016 The citation records this snapshot. The page link may show a newer release later.	USD 14.68 million Exact value Exact value: 14681000 USD 2020-01-01 – 2020-12-31: 14681000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2020-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 14681000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14681000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000016/autl-20221231.htm#2377343 Filing: 000173046323000016 The citation records this snapshot. The page link may show a newer release later.	−USD 132.44 million Calculation and evidence -117758000 − 14681000 USD Exact free cash flow: -132439000 USD 2020-01-01 – 2020-12-31: -117758000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 14681000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2020-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -132439000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117758000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000016/autl-20221231.htm#2373184 Filing: 000173046323000016 Input fundies:CapitalExpenditure: 14681000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000016/autl-20221231.htm#2377343 Filing: 000173046323000016 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 142.1 million Exact value Exact value: -142096000 USD 2021-01-01 – 2021-12-31: -142096000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2021-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -142096000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -142096000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#3027836 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	−USD 117.86 million Exact value Exact value: -117861000 USD 2021-01-01 – 2021-12-31: -117861000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2021-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -117861000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117861000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2483525 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	USD 8.86 million Exact value Exact value: 8857000 USD 2021-01-01 – 2021-12-31: 8857000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2021-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 8857000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8857000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2486459 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	−USD 126.72 million Calculation and evidence -117861000 − 8857000 USD Exact free cash flow: -126718000 USD 2021-01-01 – 2021-12-31: -117861000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 8857000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2021-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -126718000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117861000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2483525 Filing: 000173046324000048 Input fundies:CapitalExpenditure: 8857000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2486459 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 148.84 million Exact value Exact value: -148839000 USD 2022-01-01 – 2022-12-31: -148839000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2022-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -148839000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -148839000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#3027051 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	−USD 112.31 million Exact value Exact value: -112308000 USD 2022-01-01 – 2022-12-31: -112308000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2022-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -112308000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -112308000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2482866 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	USD 10.84 million Exact value Exact value: 10841000 USD 2022-01-01 – 2022-12-31: 10841000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2022-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 10841000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10841000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2485862 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.	−USD 123.15 million Calculation and evidence -112308000 − 10841000 USD Exact free cash flow: -123149000 USD 2022-01-01 – 2022-12-31: -112308000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 10841000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2022-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -123149000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -112308000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2482866 Filing: 000173046324000048 Input fundies:CapitalExpenditure: 10841000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000048/autl-20231231.htm#2485862 Filing: 000173046324000048 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 208.38 million Exact value Exact value: -208383000 USD 2023-01-01 – 2023-12-31: -208383000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2023-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -208383000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -208383000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm#2892660 Filing: 000173046325000019 The citation records this snapshot. The page link may show a newer release later.	−USD 145.59 million Exact value Exact value: -145587000 USD 2023-01-01 – 2023-12-31: -145587000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2023-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -145587000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -145587000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm#2252301 Filing: 000173046325000019 The citation records this snapshot. The page link may show a newer release later.	USD 10.99 million Exact value Exact value: 10986000 USD 2023-01-01 – 2023-12-31: 10986000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2023-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 10986000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10986000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm#2254683 Filing: 000173046325000019 The citation records this snapshot. The page link may show a newer release later.	−USD 156.57 million Calculation and evidence -145587000 − 10986000 USD Exact free cash flow: -156573000 USD 2023-01-01 – 2023-12-31: -145587000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 10986000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2023-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -156573000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -145587000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm#2252301 Filing: 000173046325000019 Input fundies:CapitalExpenditure: 10986000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm#2254683 Filing: 000173046325000019 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 220.66 million Exact value Exact value: -220662000 USD 2024-01-01 – 2024-12-31: -220662000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2024-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -220662000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -220662000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2970021 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	−USD 206.27 million Exact value Exact value: -206271000 USD 2024-01-01 – 2024-12-31: -206271000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2024-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -206271000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -206271000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2264270 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	USD 22.08 million Exact value Exact value: 22075000 USD 2024-01-01 – 2024-12-31: 22075000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2024-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 22075000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266617 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	−USD 228.35 million Calculation and evidence -206271000 − 22075000 USD Exact free cash flow: -228346000 USD 2024-01-01 – 2024-12-31: -206271000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 22075000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2024-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -228346000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -206271000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2264270 Filing: 000173046326000038 Input fundies:CapitalExpenditure: 22075000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266617 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 287.53 million Exact value Exact value: -287528000 USD 2025-01-01 – 2025-12-31: -287528000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Net Income: -287528000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -287528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2969247 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	−USD 283.57 million Exact value Exact value: -283568000 USD 2025-01-01 – 2025-12-31: -283568000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Operating Cash Flow: -283568000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -283568000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2263616 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	USD 19.04 million Exact value Exact value: 19043000 USD 2025-01-01 – 2025-12-31: 19043000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Capital Expenditure: 19043000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19043000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266025 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.	−USD 302.61 million Calculation and evidence -283568000 − 19043000 USD Exact free cash flow: -302611000 USD 2025-01-01 – 2025-12-31: -283568000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 19043000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Autolus Therapeutics plc · 2025-12-31 Autolus Therapeutics plc (edgar:1730463) Free cash flow: -302611000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:30:35Z Snapshot: 689108cab55a83286ad21950e8a21eb1404f8b8d9cff3d19921d3e9e6401c49e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1730463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -283568000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2263616 Filing: 000173046326000038 Input fundies:CapitalExpenditure: 19043000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/autl-20251231.htm#2266025 Filing: 000173046326000038 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

89 filings · 2,436 latest values · 2,436 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001730463, 1730463, AUTL, edgar:1730463

Also known as AUTOLUS THERAPEUTICS PLC, Autolus Therapeutics Ltd, Autolus Therapeutics plc, Autolus Therapeutics plc

Autolus Therapeutics plc

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation